Cargando…

Risks of using SSRI / SNRI antidepressants during pregnancy and lactation

At present, affective disorders are among the most commonly diagnosed mental diseases. In pregnancy, they can occur as pre-delivery depression, recurrent depressive disorder or postnatal depression. The estimated prevalence of depressive disorders in pregnancy is approximately 9–16%, with some stati...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubovicky, Michal, Belovicova, Kristína, Csatlosova, Kristína, Bogi, Eszter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Slovak Toxicology Society SETOX 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096863/
https://www.ncbi.nlm.nih.gov/pubmed/30123033
http://dx.doi.org/10.1515/intox-2017-0004
_version_ 1783348183475159040
author Dubovicky, Michal
Belovicova, Kristína
Csatlosova, Kristína
Bogi, Eszter
author_facet Dubovicky, Michal
Belovicova, Kristína
Csatlosova, Kristína
Bogi, Eszter
author_sort Dubovicky, Michal
collection PubMed
description At present, affective disorders are among the most commonly diagnosed mental diseases. In pregnancy, they can occur as pre-delivery depression, recurrent depressive disorder or postnatal depression. The estimated prevalence of depressive disorders in pregnancy is approximately 9–16%, with some statistics reporting up to 20%. Approximately 2–3% of pregnant women take antidepressants during pregnancy, and the number of mothers treated increases by birth to 5–7%. Treatment of depression during pregnancy and breastfeeding is a controversial issue, as antidepressants can negatively affect the developing fetus. According to epidemiological studies, the effects of treated depression in pregnancy are related to premature birth, decreased body weight of the child, intrauterine growth retardation, neonatal adaptive syndrome, and persistent pulmonary hypertension. However, untreated depression can adversely affect maternal health and increase the risk of preeclampsia and eclampsia, as well as of subsequent postnatal depression, which can lead to disruption of the mother-child relationship. Based on the above mentioned facts, the basic question arises as to whether or not to treat depression during pregnancy and lactation.
format Online
Article
Text
id pubmed-6096863
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Slovak Toxicology Society SETOX
record_format MEDLINE/PubMed
spelling pubmed-60968632018-08-17 Risks of using SSRI / SNRI antidepressants during pregnancy and lactation Dubovicky, Michal Belovicova, Kristína Csatlosova, Kristína Bogi, Eszter Interdiscip Toxicol Minireview At present, affective disorders are among the most commonly diagnosed mental diseases. In pregnancy, they can occur as pre-delivery depression, recurrent depressive disorder or postnatal depression. The estimated prevalence of depressive disorders in pregnancy is approximately 9–16%, with some statistics reporting up to 20%. Approximately 2–3% of pregnant women take antidepressants during pregnancy, and the number of mothers treated increases by birth to 5–7%. Treatment of depression during pregnancy and breastfeeding is a controversial issue, as antidepressants can negatively affect the developing fetus. According to epidemiological studies, the effects of treated depression in pregnancy are related to premature birth, decreased body weight of the child, intrauterine growth retardation, neonatal adaptive syndrome, and persistent pulmonary hypertension. However, untreated depression can adversely affect maternal health and increase the risk of preeclampsia and eclampsia, as well as of subsequent postnatal depression, which can lead to disruption of the mother-child relationship. Based on the above mentioned facts, the basic question arises as to whether or not to treat depression during pregnancy and lactation. Slovak Toxicology Society SETOX 2017-09 2018-02-14 /pmc/articles/PMC6096863/ /pubmed/30123033 http://dx.doi.org/10.1515/intox-2017-0004 Text en Copyright © 2017 SETOX & Institute of Experimental Pharmacology and Toxicology, SASc. https://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License. (CC BY-NC-ND 4.0)
spellingShingle Minireview
Dubovicky, Michal
Belovicova, Kristína
Csatlosova, Kristína
Bogi, Eszter
Risks of using SSRI / SNRI antidepressants during pregnancy and lactation
title Risks of using SSRI / SNRI antidepressants during pregnancy and lactation
title_full Risks of using SSRI / SNRI antidepressants during pregnancy and lactation
title_fullStr Risks of using SSRI / SNRI antidepressants during pregnancy and lactation
title_full_unstemmed Risks of using SSRI / SNRI antidepressants during pregnancy and lactation
title_short Risks of using SSRI / SNRI antidepressants during pregnancy and lactation
title_sort risks of using ssri / snri antidepressants during pregnancy and lactation
topic Minireview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096863/
https://www.ncbi.nlm.nih.gov/pubmed/30123033
http://dx.doi.org/10.1515/intox-2017-0004
work_keys_str_mv AT dubovickymichal risksofusingssrisnriantidepressantsduringpregnancyandlactation
AT belovicovakristina risksofusingssrisnriantidepressantsduringpregnancyandlactation
AT csatlosovakristina risksofusingssrisnriantidepressantsduringpregnancyandlactation
AT bogieszter risksofusingssrisnriantidepressantsduringpregnancyandlactation